An experimental therapeutic cancer vaccine, SNAPvax, designed by Robert Seder, M.D., and colleagues at the NIAID Vaccine Research Center together with collaborators from Vaccitech North America, induced "two distinct and desirable immune system responses that led to significant tumor regression in mice," report investigators from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Vaccitech has announced plans to advance the SNAPvax platform for use in treating human papilloma virus-associated cancer in 2023, the NIH report noted. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VACC:
- Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD – The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300
- Vaccitech doses first patients in HBV003, a Phase 2b trial of VTP-300
- Vaccitech announce publication of research on its SNAPvax
- Vaccitech to Present at Upcoming October Investor & Scientific Conferences
- Vaccitech Promotes Gemma Brown as Chief Financial Officer